期刊文献+

APRIL siRNA对 SW480裸鼠移植瘤的影响

Effect of APRIL siRNA in Nude Mice with SW480
下载PDF
导出
摘要 目的:探讨增殖诱导配体(APRIL)基因在 SW480裸鼠移植瘤中的作用。方法建立人结直肠癌(CRC)裸鼠移植瘤模型并随机分为3组,瘤块内分别注射 APRIL siRNA、空载体和 PBS液。RT-PCR和免疫组织化学法(IHC)检测 A-PRIL水平和蛋白表达,人基质金属蛋白酶抑制因子-3(IHC检测TIMP-3),多配体蛋白聚糖-1(Syndecan-1,又名CD138)和基质金属蛋白酶-9(MMP-9)蛋白表达。结果①注射PBS组裸鼠移植瘤瘤块质量(2.15±0.30 g)明显高于注射 APRIL siRNA组(0.95±0.15 g,P<0.05),与注射空载体组(2.20±0.25 g)比较差异无统计学意义(P>0.05)。②注射 PBS组裸鼠 APRIL mRNA/18S rRNA比值(2.48±0.25)明显高于注射 APRIL siRNA组(0.39±0.15,P<0.05),与注射空载体组(2.51±0.30)比较差异无统计学意义(P>0.05)。③注射 APRIL siRNA 明显抑制 SW480细胞侵袭转移,3组 TIMP-3 Allred得分为7.70±0.35,1.10±0.16和1.15±0.12;Syndecan-1蛋白分别为7.80±0.30,1.05±0.20和1.10±0.22;MMP-9蛋白分别为1.20±0.10,8.00±0.25和8.20±0.20。结论 APRIL与人结直肠癌细胞 SW480的生长和转移有密切关系。 Objective To investigate the role of APRIL in SW480 cell line.Methods The CRC model was established in the nude mice,all the mice were divided into 3 groups,the mice were separately treated with APRIL siRNA,pGC-vector and PBS solution.The APRIL mRNA was detected by RT-PCR and the APRIL protein was surveyed by the way of immunohis-tochemistry (IHC).The proteins of TIMP-3,Syndecan-1and MMP-9 also were assessed by IHC.Results ①Tumor mass in the group of nude mice injected with PBS (2.15±0.30 g)was significantly higher than the injection APRIL siRNA group (0.95±0.15 g,P〈0.05),and was not statistically significant (P〉0.05)compared with the injection of empty vector group (2.20±0.25 g).②APRIL mRNA/18S rRNA ratio (2.48±0.25)in the group of mice injected with PBS was signifi-cantly higher than the injection APRIL siRNA group (0.39±0.15,P〈0.05),and was not statistically significant (P〉0.05)compared with the injection of empty vector group (2.51±0.30).③SW480 cells injected with APRIL siRNA signifi-cantly inhibited invasion and metastasis.TIMP-3 Allred scores in three groups were 7.70±0.35,1.10±0.16 and 1.15± 0.12,Syndecan-1 protein was 7.80±0.30,1.05±0.20 and 1.10±0.22 MMP-9 protein was 1.20 ±0.10,8.00±0.25 and 8.20±0.20,respectively.Conlusion APRIL was closely connected with the growth and metabasis of CRC.
出处 《现代检验医学杂志》 CAS 2014年第6期55-58,共4页 Journal of Modern Laboratory Medicine
基金 江苏省“六大人才高峰”资助项目(WS-066).
  • 相关文献

参考文献8

  • 1潘湘涛,陆晔,王金湖,程旭,李蓉,严敏.淋系血液肿瘤患者BAFF和APRIL表达及意义[J].现代检验医学杂志,2010,25(1):74-76. 被引量:1
  • 2Destouches D,Huet E, Sader M, et al. Multivalentpseudopeptides targeting cell surface nucieoproteinsinhibit cancer cell invasion through tissue inhibitor ofmetalloproteinases 3 (TIMP-3) release [J]. J BiolChem,2012,287(52) :43685-43693.
  • 3Catasus L,Pons C,Munoz J, et al. Promoter hyperm-ethylation contributes to TIMP3 down-regulation inhigh stage endometrioid endometrial carcinomas[J].Histopathology,2013,62(4) :632-641.
  • 4Gupta A,Cao W,Sadashivaiah K,et al. Promising no-ninvasive cellular phenotype in prostate cancer cellsknockdown of matrix metalloproteinase 9[J]. Scientif-ic World Journal, 2013//http;//dx, doi. org/10.1155/2013/493689.
  • 5王行,张骥,胡嘉琪,张霰.硫酸乙酰肝素蛋白聚糖与增殖诱导配体在肺癌中的相关性研究[J].现代检验医学杂志,2010,25(6):19-22. 被引量:2
  • 6Yilmaz Y ? Eren F?Colak Y, et al. Hepatic expressionand serum levels of syndecan 1 (CD138) in patientswith nonalcoholic fatty liver disease[J]. Scand J Gas-troenterol ?2012,47(12):1488-1493.
  • 7Mitseiou A,Skoufi U,Tsimogiannis KE,et al. Associ-ation of syndecan-1 with angiogenesis-related mark-ers ,extracellular matrix components,and clinicopath-ological features in colorectal carcinoma[J]. Antican-cer Reseanh,2012,32(9):3977-3985.
  • 8Metwaly HA, Al-Gayyar MM,Eletreby S,et al. Rele-vance of serum levels of interleukin-6 and syndecan-1in patients with hepatocellular carcinoma [ J ]. SciPharm,2012,80(1) .179-188.

二级参考文献22

  • 1Baker KP. Blys--an essential survival factor for B cells : basic biology,links to pathology and therapeutic targe [J]. Autaimmun Rev, 2004,3 (5) : 368-375.
  • 2Schneider P. The role of APRIL and BAFF in lymphocyte activation[J]. Curr Opin Immunol, 2005,17 : 282-289.
  • 3Ding C. Belimumab an anti-BlyS human monoclonal antibody for potential treatment of inflammatory autoirnmune[J]. Expert Opinl Biol Ther, 2008,8 (11) : 1805-1814.
  • 4Shivakumar L,Ansell S. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferationinducing ligand in hematologic malignancies [J]. Clin Lymphoma Myeloma , 2006,7 (2) : 106-108.
  • 5Ansell SM,Novak AJ,Ziesmer S,et al. Serum BIyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma[J]. Am J Hematol , 2009 , 84 ( 2 ) : 71- 73.
  • 6Levesque MV . Translational Mini-Review Series on B Cell-Directed Therapies:Recent advances in B cell- directed biological therapies for autoimmune disorders[J]. Clin Exp Immunol, 2009,157(2) : 198-208.
  • 7Emmerich F, Bal G, Barakat A,et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic throbocytopenic purpura [J]. Br J Haematol, 2007,136 (2) : 309-334.
  • 8Zhou Z,Chen Z,Li H,et al. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura[J]. Autoimmunity,2009,42(2) : 112-119.
  • 9Juuti A,Nordling S,Lundin J,et al.Sydecan-1 exp-ression-a novel prognostic marker in pancreatic cancer[J].Oncology,2005,68(2-3):97-106.
  • 10Kiviniemi J,Kallajoki M,Kujala I,et al.Altered expression of syndecan-1 in prostate cancer[J].APMIS,2004,112(2):89-97.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部